The RAPTER consortium integrates computational modeling, experimental immunology, and data-driven vaccine evaluation. Featured publications highlight foundational framework development, methodological advances, and applied vaccine studies across pathogens and platforms.
Kubicek-Sutherland JZ, McMahon B, Skowronski E, Webb RP, Pals T (2026).
Editorial: Towards the rapid and systematic assessment of vaccine technologies.
Frontiers in Immunology, 17:1816160.
Defines the conceptual and strategic foundation for systematic vaccine platform assessment.
Anderson LN, et al. (2025).
Computational tools and data integration to accelerate vaccine development: challenges, opportunities, and future directions.
Frontiers in Immunology, 16:1502484.
Outlines data integration strategies and computational approaches underlying RAPTER.
Wilding KM, et al. (2025).
A consensus mathematical model of vaccine-induced antibody dynamics for multiple vaccine platforms and pathogens.
Frontiers in Immunology, 16:1596518.
Presents a cross-platform model of vaccine-induced antibody kinetics.
Biryukov SS, et al. (2025).
Comparison of homologous and heterologous vaccination strategies for combating disease caused by Burkholderia pseudomallei.
Frontiers in Immunology, 16:1596265.
Demonstrates application of comparative platform strategies in a high-consequence pathogen model.
Frontiers in Immunology Special Issue:
Towards the rapid and systematic assessment of vaccine technologies
RAPTER-supported curation of a multi-paper collection advancing systematic vaccine platform evaluation.
Publications are listed in reverse chronological order.
Kubicek-Sutherland JZ, et al. (2026).
Editorial: Towards the rapid and systematic assessment of vaccine technologies.
Front. Immunol. 17:1816160.
Stromberg ZR, et al. (2026).
An mRNA vaccine encoding the Ebola virus glycoprotein induces high neutralizing antibody titers and provides strong protection against lethal infections in mouse models.
Front. Immunol. 16:1682418.
Hirsch AH, et al. (2025).
Heterologous prime-pull mucosal vaccination with an adjuvanted RBD vaccine elicits robust IgA production and protects against SARS-CoV-2.
Front. Immunol. 16:1673460.
Davies ML, et al. (2025).
Immune responses following DNA vaccination by needle-free injection against Burkholderia pseudomallei hemolysin co-regulated protein 1.
Front. Immunol. 16:1612540.
Elko EA, et al. (2025).
PepSeq as a highly multiplexed platform for melioidosis antigen discovery and vaccine development.
Front. Immunol. 16:1605758.
Biryukov SS, et al. (2025).
Comparison of homologous and heterologous vaccination strategies for combating disease caused by Burkholderia pseudomallei.
Front. Immunol. 16:1596265.
Wilding KM, et al. (2025).
A consensus mathematical model of vaccine-induced antibody dynamics for multiple vaccine platforms and pathogens.
Front. Immunol. 16:1596518.
Wang R, et al. (2025).
Nanoparticle approaches for manipulating cytokine delivery and neutralization.
Front. Immunol. 16:1592795.
Bowley TY, et al. (2025).
Methods integrating innate and adaptive immune responses in human in vitro immunization assays.
Front. Immunol. 16:1584852.
Sengyee S, et al. (2025).
Melioidosis vaccines: recent advances and future directions.
Front. Immunol. 16:1582113.
Anderson LN, et al. (2025).
Computational tools and data integration to accelerate vaccine development: challenges, opportunities, and future directions.
Front. Immunol. 16:1502484.
Harris DC, et al. (2024).
Quantification of heterogeneity in human CD8+ T cell responses to vaccine antigens: an HLA-guided perspective.
Front. Immunol. 15:1420284.
Bergstrom C, et al. (2024).
mRNA vaccine platforms to prevent bacterial infections.
Trends Mol. Med. 30(6):524–526.